Famotidine Research Progress

Aamir Jalal Al Mosawi*

Aamir Jalal Al Mosawi*

Volume2-Issue1
Dates: Received: 2020-12-23 | Accepted: 2021-01-09 | Published: 2021-01-11
Pages: 021-023

Abstract

There has been an increasing interest in famotidine research within the scientific medical community because of the emerging preliminary evidence suggesting its possible beneficial role in patients with COVID‑19. The aim of this paper to provide an overview of famotidine research progress relevant to COVID‑19.

FullText HTML FullText PDF DOI: 10.37871/jbres1181

Certificate of Publication

Copyright

How to cite this article

Al Mosawi AJ. Famotidine Research Progress. J Biomed Res Environ Sci. 2021 Jan 11; 2(1): 021-023. doi: 10.37871/jbres1181, Article ID: jbres1181

Subject area(s)

Gastroenterology

References

Al-Mosawi AJ. Bat-Human Coronaviruses: A Global Health Problem and a Therapeutic Challenge. Journal of Medical Clinical Case Reports. 2020;2:1-3. doi: 10.5281/zenodo.3878405
Al-Mosawi AJ. Bat-Human Coronaviruses: Keys to the therapeutic challenge. 1st ed., Saarbrücken; LAP Lambert Academic Publishing. 2020.
Al-Mosawi AJ. Bat-human Coronaviruses: Keys to The Therapeutic Challenge. 1st ed., Baghdad; Iraq Headquarter of Copernicus Scientists International Panel Publishing. 2020
Al-Mosawi AJ. The Use of the Available Research Evidence to Crack the Padlock of Sars-CoV-2. Journal of Virology Research & Reports. 2020;1:1-8. doi: 10.5281/zenodo.3970844
Al-Mosawi AJ. Using research evidence to crack the padlock of SARS-CoV-2. 1st ed., LAP Lambert Academic Publishing, Saarbrücken; Germany. 2020.
Al-Mosawi AJ. The use of the available research evidence to crack the padlock of SARS-CoV-2.1st ed., Baghdad; Iraq Headquarter of Copernicus Scientists International Panel Publishing. 2020.
Al-Mosawi AJ. Trump’s covid-19 treatment: Is there any better approach? Scholar’s press: 2020.
Al-Mosawi AJ. Remdesivir research progress: An overview of the emerging evidence. Biomedical Research & Environmental Sciences 2020 Oct 14; 6(10): 216-218. Doi: 10.37871/jbres1146
Sen Gupta PS, Biswal S, Singha D, Rana MK. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn 2020 Jun 24:1-7. PMID: 32579065. Doi: 10.1080/07391102.2020.1784795.
Ortega JT, Serrano ML, Jastrzebska B. Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative Against SARS-CoV2: An in silico analysis. Biomolecules 2020 Jun 24; 10(6):954. PMID: 32599963. Doi: 10.3390/biom10060954.
Kurzrock R, Auber M, Mavligit GM. Cimetidine therapy of herpes simplex virus infections in immunocompromised patients. Clin Exp Dermatol 1987 Sep; 12(5):326-31. PMID: 3446417.Doi: 10.1111/j.1365-2230.1987.tb02501.x.
Kapińska-Mrowiecka M, Turowski G. Skuteczność cymetydyny w leczeniu półpaśca w pierwszych 5 dniach od ujawnienia choroby [Efficacy of cimetidine in treatment of Herpes zoster in the first 5 days from the moment of disease manifestation]. Pol Tyg Lek 1996 Jun; 51(23-26):338-9. Polish. PMID: 9273526.
Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci. 1996; 59(23):PL 365-70. PMID: 8950301. Doi: 10.1016/s0024-3205(96)00553-x.
Harcourt JP, Worley G, Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 1999 Dec 5; 51(2):109-13. Doi: 10.1016/s0165-5876(99)00279-7. PMID: 10619624.
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Res Sq. 2020 Jun 22:rs.3.rs-30934. PMID: 32702719.Doi: 10.21203/rs.3.rs-30934/v2.
Hogan Ii RB, Hogan Iii RB, Cannon T, Rappai M, Studdard J, Paul D, Dooley TP. Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther 2020 Aug; 63:101942. PMID: 32871242Doi: 10.1016/j.pupt.2020.101942.
Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with covid-19. Am J Gastroenterol 2020 Oct; 115(10):1617-1623. PMID: 32852338.Doi: 10.14309/ ajg.00000 00000000832.
Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 2020 Sep; 69(9):1592-1597. PMID: 32499303 Doi: 10.1136/gutjnl-2020-321852.
Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA; Famotidine Research Group. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22. PMID: 32446698; PMCID: PMC7242191.
Al-Mosawi AJ. Использование данных исследований для взлома замка SARS-CoV-2 (Russian edition) Sciencia Scripts: 2020 (ISBN-13:978-620-2-60758-2).
Al-Mosawi AJ. Utilização de provas de investigação para rachar o cadeado da SRA-CoV-2 (Portuguese edition) .Edições Nosso Conhecimento: 2020 (ISBN-13: 978-620-2-60757-5).
Al-Mosawi AJ. Użycie dowodów naukowych do złamania kłódki SARS-CoV-2 (Polish edition) Wnictwo Nasza Wiedza: 2020 (ISBN-13: 978-620-2-60756-8).
Al-Mosawi AJ. Gebruik van onderzoeksmateriaal voor het kraken van het hangslot van SARS-CoV-2 (Dutch edition). Uitgeverij Onze kennis: 2020 (ISBN-13:978-620-2-60755-1).
Al-Mosawi AJ. C SARS-CoV-2 (Italian edition) Edizioni Sapien: 2020 (ISBN-13: 978-620-2-60753-7).
Al-Mosawi AJ. Utilisation des résultats de la recherche pour briser le cadenas du SRAS-CoV-2 (French edition) Editions Notre Savoir: 2020 (ISBN-13: 978-620-2-60752-0).
Mosawi AJ. El uso de pruebas de investigación para romper el candado del SARS-CoV-2 (Spanish edition). Ediciones Nuestro Conocimiento: 2020 (ISBN-13:978-620-2-60751-3)
Al-Mosawi AJ. Verwendung von Forschungsergebnissen zum Knacken des Vorhängeschlosses von SARS-CoV-2 (German edition). Verlag Unser Vissen: 2020 (ISBN-13:978-620-2-60750-6).